Most Potent GHRP Research Compound WADA Prohibited

Hexarelin

Examorelin · EP-23905 · MF-6003 · His-D-2MeTrp-Ala-Trp-DPhe-Lys-NH2

"The most potent growth hormone-releasing peptide ever synthesised — 10× more potent than GHRP-6. But hexarelin's most distinctive feature isn't its GH-releasing power: it's a second receptor in the heart (CD36) that produces direct cardioprotective effects completely independent of growth hormone. No other GHRP does this."

Structure
6 AA hexapeptide · synthetic GHRP
GH potency
10× GHRP-6 · 2-3× GHRP-2
Unique receptor
CD36 on cardiomyocytes — GH-independent
Desensitisation
85% response at 28 days (vs 40-50% for other GHRPs)
WADA
Prohibited at all times
Origin & Background

The GHRP engineered for maximum potency

Hexarelin was synthesised by Mediolanum Farmaceutici in Milan in 1972, building on Cyril Bowers' discovery that enkephalin analogues could stimulate GH release. It is a hexapeptide (6 amino acids: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), where the critical innovation is the D-2-methyl-Tryptophan substitution — this modification gives hexarelin its exceptional potency and resistance to enzymatic degradation relative to its parent compound GHRP-6.

The foundational 1994 Ghigo clinical study established hexarelin as the most potent GH secretagogue in its class by a substantial margin. At 1-2 μg/kg IV in healthy volunteers, hexarelin elicited robust GH peaks via multiple routes including intravenous, subcutaneous, intranasal, and oral. The Phase II clinical programme explored both GH deficiency diagnosis and cardiac indications — ultimately discontinued for commercial reasons rather than safety failures.

The discovery of hexarelin's cardiac receptor (CD36) by Papotti et al. (2000) and Bodart et al. (2002) transformed understanding of the GHRP family. CD36, an 88 kDa glycoprotein on cardiomyocytes and microvascular endothelial cells, is not a GH receptor — it is a scavenger receptor involved in fatty acid transport and cellular signalling. Hexarelin's binding to CD36 in cardiac tissue produces cardioprotective effects that persist even in hypophysectomised animals with no pituitary GH response. The heart has its own hexarelin receptor that operates completely separately from the pituitary axis.

Hexarelin vs Ipamorelin: Hexarelin is the most potent GHRP; ipamorelin is the most selective. Hexarelin elevates cortisol and prolactin alongside GH — ipamorelin does not. For pure GH optimisation with the cleanest side effect profile, ipamorelin is generally preferred. For maximum GH output or cardiac applications, hexarelin's unique profile becomes relevant. Choose based on your goals and tolerance for the cortisol/prolactin effects.

Science & Mechanism

Dual receptor biology — GHS-R1a and CD36

Mechanism of Action

1
GHS-R1a agonism (pituitary): Hexarelin binds ghrelin receptors in the hypothalamus and pituitary with higher affinity than any other synthetic GHRP. Activates PKC signalling and calcium mobilisation → GH pulse release. 10-fold higher potency than GHRP-6, 2-3 fold higher than GHRP-2 in head-to-head GH release assays.
2
Resistance to desensitisation: Where GHRP-2 and GHRP-6 show 40-50% reduction in GH response after 28 days of continuous use, hexarelin maintains ~85% of initial response. The methyltryptophan modification appears to influence receptor binding kinetics and allosteric modulation, reducing tachyphylaxis.
3
CD36 receptor activation (heart): The most distinctive hexarelin mechanism. CD36 is expressed at highest density in human myocardium — higher than any other peripheral tissue. Bodart et al. (2002) used photoaffinity cross-linking to identify Met169 within the CD36-(Asn132-Glu177) sequence as the primary hexarelin contact residue. Crucially: hexarelin's cardioprotection was completely absent in CD36-null mice, confirming receptor dependence.
4
Ischaemia/reperfusion protection: Pre- or post-treatment with hexarelin (1 nM) protected mouse cardiomyocytes from I/R injury by recovering phospholamban phosphorylation and sarcoplasmic reticulum calcium handling. In vivo: hexarelin reduced infarct size by 40-45% when administered 30 minutes before ischaemic insult, activating Akt and ERK1/2 survival kinases.
5
Human cardiac proof-of-concept: 1999 study: 7 patients with GH deficiency and left ventricular failure received IV hexarelin. GH response was negligible (pituitary-deficient patients). Despite no GH release, hexarelin increased LVEF — the first proof in humans of GH-independent cardiac effects mediated by myocardial GHS receptors.
6
Anti-apoptosis in cardiomyocytes: Hexarelin significantly decreased angiotensin II-induced apoptosis in neonatal rat cardiomyocytes and inhibited doxorubicin-induced apoptosis in H9c2 cells and endothelial cells — providing additional mechanisms beyond the ischaemia/reperfusion protection.
Community Voices

What people report

Anecdotal ReportNot medical evidence · Research use

"Switched to hexarelin from GHRP-2 for a 12-week phase. Noticeably stronger GH pulse subjectively — better sleep depth and recovery. The hunger side effect is much less than GHRP-6 but the cortisol elevation is real. I can feel it as a mild background arousal. Worth it for the potency but I cycled back to ipamorelin for maintenance."

Male, 41, experienced peptide user. The cortisol elevation is the most consistently reported distinguishing side effect vs ipamorelin. Hunger is moderate (less than GHRP-6 but more than ipamorelin). For users wanting maximum GH pulse with more hunger and cortisol tolerance, hexarelin is the clear choice in the GHRP class.

Clinical observationMedical professional observation

"The cardiac data on hexarelin is something I follow closely. The CD36 mechanism is genuinely novel — no other peptide in clinical use has this receptor profile. Whether the preclinical cardiovascular protection translates to outcomes in human patients is still unproven, but the mechanistic case is stronger than for most peptides I've seen."

Cardiologist commentary on hexarelin research. The Papotti and Bodart cardiac receptor papers are some of the most rigorously conducted receptor pharmacology studies in the GHRP literature, providing a high level of confidence in the mechanism even with limited human outcome data.

Benefits & Evidence

What the data shows

💪
Maximum GH release in class
Ghigo 1994: most potent GH secretagogue tested across IV, SubQ, intranasal, and oral routes. 10× more potent than GHRP-6. 85% maintained response at 28 days vs 40-50% for competitors. Synergistic with GHRH — combination produces 2-3× greater GH than either alone.
● Strong — Phase 2 human trials (Ghigo group)
❤️
Cardioprotection — CD36 mediated
Reduces I/R infarct size 40-45% in animal models. Human proof-of-concept: improved LVEF in GH-deficient patients with LV failure with no GH response — confirming the cardiac mechanism is GH-independent. Protects against angiotensin II and doxorubicin-induced cardiomyocyte apoptosis.
● Moderate — animal models + human proof-of-concept
💤
Sleep quality and recovery
Like all GHRPs, GH elevation translates to improved slow-wave sleep quality. Hexarelin's greater GH potency may produce correspondingly stronger sleep benefits. Consistently reported as one of the most noticeable subjective effects.
● Moderate — consistent with GH class effects
Safety First

Risks & considerations

⚠️
Safe in Phase 2 trials but more hormonal side effects than selective GHRPs. Zero serious adverse events across 500+ subjects in published studies. Main practical concern vs ipamorelin: dose-dependent cortisol and prolactin elevation. Cortisol returns to normal between doses; prolactin elevation is modest (23% above baseline, within normal range). Select ipamorelin for clean GH with no cortisol effects; select hexarelin when maximum GH or cardiac benefits are the priority.
Mild
Cortisol and ACTH elevation — dose-dependent. More pronounced than GHRP-6 at equivalent doses. Cortisol returns to normal between doses; no sustained HPA axis overstimulation at 16 weeks twice-daily in clinical studies.
Mild
Prolactin elevation — modest (23% above baseline). Remains within normal range throughout 16-week twice-daily dosing. Less than might be expected given potency.
Mild
Appetite stimulation — 5-15% incidence. Less than GHRP-6 (~30-50% incidence). More than ipamorelin (negligible). Caused by GHS-R1a activation in hypothalamic feeding centres.
Mild
Water retention — mild fluid retention at higher doses, similar to class effects.

⚠ Key Warnings

WADA prohibited at all times — detection methods established for competitive athletes.
Not FDA-approved. Research compound only. No compounding pharmacy availability.
If cortisol elevation is a concern (e.g., managing stress, sleep, body composition), ipamorelin is the preferred alternative with equivalent GH protocols.
The cardiac benefits are preclinical + proof-of-concept only. Do not use hexarelin as a cardiac medication — this is not a validated therapeutic application.
Synergy Stack

Maximising the GH pulse

Hexarelin's primary use case is maximum GH pulse generation. The stack focuses on amplifying the GH response and making it count for body composition and recovery.

💊 Synergistic combinations
+ GHRH (Mod-GRF 1-29 or CJC-1295)
100mcg hexarelin + 100mcg GHRH · simultaneously
Strong evidence
GHRH + hexarelin combination produces 2-3× greater GH than either alone — the most potent GH stimulation achievable with peptides. GHRH acts on GHRH receptors; hexarelin acts on GHS-R1a — the two pathways are synergistic, not additive. The gold standard protocol for maximum GH pulse.
Fasted injection before sleep
Inject 30-60min before bed · no carbs for 2h prior
Strong evidence
GH is primarily released during slow-wave sleep. Somatostatin (GH's inhibitor) is highest post-meal. Injecting fasted amplifies hexarelin's GH response. Aligns the pharmacokinetic peak with the natural sleep-related GH surge for maximum effect.
Protein (2g/kg/day)
Adequate leucine-rich protein throughout day
Strong evidence
GH drives IGF-1-mediated protein synthesis — but amino acids are the required substrate. Without adequate dietary protein, the anabolic signal from elevated GH has no building blocks to work with.
⏱ Protocol Notes
Typical dose: 100-200mcg SubQ, 1-3× daily. Most commonly before bed ± pre-workout. Always fasted or 2+ hours post-meal. Standard cycle: 8-12 weeks on, 4 weeks off. Pulsatile use (2× daily) preferred over continuous to reduce desensitisation, though hexarelin is more resistant to this than other GHRPs.

Disclaimer: Hexarelin is not approved for human use. WADA prohibited. Not available through compounding pharmacies. Research chemical sourcing only — purity and dosing accuracy cannot be guaranteed.

Honest Assessment

Editor's summary

Hexarelin occupies a unique position in the GHRP family: the highest potency for GH release, combined with the only cardiac receptor mechanism in the class. Its 10-fold potency advantage over GHRP-6 is clinically relevant. The CD36 cardiac mechanism is one of the most rigorously characterised receptor pharmacology stories in peptide science — the receptor has been identified, the binding site has been mapped, and the GH-independence has been confirmed with knockout animal models.

The honest tradeoff: the cortisol and prolactin elevation that comes with its potency makes it less clean than ipamorelin for people who want GH benefits without HPA axis stimulation. For most people pursuing GH optimisation, the ipamorelin/CJC-1295 combination offers comparable body composition results with a cleaner profile. Hexarelin makes sense as a higher-intensity tool — either for maximum GH output or for its cardiac properties — rather than as a general-purpose secretagogue.

Verdict
"The most potent GHRP with a uniquely characterised cardiac receptor. Best for maximum GH pulse or cardiac research applications. The cortisol/prolactin elevation makes ipamorelin the cleaner everyday choice — reach for hexarelin when you need maximum GH or care about the CD36 cardiac mechanism."